Dr. Reddy's Laboratories Limited (RDY)
Price:
14.03 USD
( - -0.06 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Elanco Animal Health Incorporated
VALUE SCORE:
8
2nd position
Perrigo Company plc
VALUE SCORE:
10
The best
Zoetis Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
NEWS
My Top 5 Biotech Stocks Big Pharma Could Buy Next
seekingalpha.com
2025-10-06 13:29:00While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
globenewswire.com
2025-08-18 08:16:00Extrovis AG Bahnhof Park 46340, Baar, Switzerland Media Relations Contact Madhu Marur madhu.marur@extrovis.com Press Release Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food and Drug Administration (USFDA).
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
zacks.com
2025-07-24 12:25:18RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript
seekingalpha.com
2025-07-23 18:09:27Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division Aman Vij - Unidentified Company Amey Chalke - JM Financial Institutional Securities Limited, Research Division Bino Joseph Pathiparampil - Elara Securities (India) Private Limited, Research Division Damayanti Kerai - HSBC Global Investment Research Foram Prashant Parekh - BOB Capital Markets Limited, Research Division Harith Mohammed Ahamed - Spark Institutional Equities Private Limited, Research Division Kunal Dhamesha - Macquarie Research Madhav Marda - Unidentified Company Fidelity Investments - Unidentified Company Neha Manpuria - BofA Securities, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Shashank Krishnakumar - Emkay Global Financial Services Ltd.
Dr. Reddy's Q1FY26 Financial Results
businesswire.com
2025-07-23 13:46:00HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.
India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says
reuters.com
2025-07-23 10:27:32Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday.
New Strong Sell Stocks for July 18th
zacks.com
2025-07-18 06:11:06ACHC, CNL and RDY have been added to the Zacks Rank #5 (Strong Sell) List on July 18, 2025.
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
zacks.com
2025-06-05 12:31:07Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
businesswire.com
2025-06-05 07:00:00HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
seekingalpha.com
2025-05-15 11:47:57I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
zacks.com
2025-05-12 10:20:42Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Generics won't be affected by Trump's pricing policy, says Dr. Reddy's
youtube.com
2025-05-12 03:51:22Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans to expand its diabetes and obesity drug offerings amid increasing competition.
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
seekingalpha.com
2025-05-09 18:03:02Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CFO Conference Call Participants Neha Manpuria - Bank of America Kunal Dhamesha - Macquarie Group Madhav Marda - Fidelity Amey Chalke - JM Financial Bino Pathiparampil - Elara Capital Krishnendu Saha - Quantum Mutual Fund Tushar Manudhane - Motilal Oswal Abdulkader Puranwala - ICICI Securities Surya Patra - PhillipCapital Shashank Krishnakumar - Emkay Global Shrikant Akolkar - Nuvama Wealth Saion Mukherjee - Nomura Operator Ladies and gentlemen, good evening, and welcome to Quarter Four and Full Year FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. [Operator Instructions] I now hand the conference over to Ms.
Dr. Reddy's Q4 & Full Year FY25 Financial Results
businesswire.com
2025-05-09 14:53:00HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
zacks.com
2025-03-31 10:31:49Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
prnewswire.com
2025-03-27 11:47:00GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
seekingalpha.com
2025-10-06 13:29:00While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
globenewswire.com
2025-08-18 08:16:00Extrovis AG Bahnhof Park 46340, Baar, Switzerland Media Relations Contact Madhu Marur madhu.marur@extrovis.com Press Release Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food and Drug Administration (USFDA).
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
zacks.com
2025-07-24 12:25:18RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript
seekingalpha.com
2025-07-23 18:09:27Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division Aman Vij - Unidentified Company Amey Chalke - JM Financial Institutional Securities Limited, Research Division Bino Joseph Pathiparampil - Elara Securities (India) Private Limited, Research Division Damayanti Kerai - HSBC Global Investment Research Foram Prashant Parekh - BOB Capital Markets Limited, Research Division Harith Mohammed Ahamed - Spark Institutional Equities Private Limited, Research Division Kunal Dhamesha - Macquarie Research Madhav Marda - Unidentified Company Fidelity Investments - Unidentified Company Neha Manpuria - BofA Securities, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Shashank Krishnakumar - Emkay Global Financial Services Ltd.
Dr. Reddy's Q1FY26 Financial Results
businesswire.com
2025-07-23 13:46:00HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.
India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says
reuters.com
2025-07-23 10:27:32Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday.
New Strong Sell Stocks for July 18th
zacks.com
2025-07-18 06:11:06ACHC, CNL and RDY have been added to the Zacks Rank #5 (Strong Sell) List on July 18, 2025.
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
zacks.com
2025-06-05 12:31:07Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
businesswire.com
2025-06-05 07:00:00HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
seekingalpha.com
2025-05-15 11:47:57I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
zacks.com
2025-05-12 10:20:42Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Generics won't be affected by Trump's pricing policy, says Dr. Reddy's
youtube.com
2025-05-12 03:51:22Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans to expand its diabetes and obesity drug offerings amid increasing competition.
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
seekingalpha.com
2025-05-09 18:03:02Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CFO Conference Call Participants Neha Manpuria - Bank of America Kunal Dhamesha - Macquarie Group Madhav Marda - Fidelity Amey Chalke - JM Financial Bino Pathiparampil - Elara Capital Krishnendu Saha - Quantum Mutual Fund Tushar Manudhane - Motilal Oswal Abdulkader Puranwala - ICICI Securities Surya Patra - PhillipCapital Shashank Krishnakumar - Emkay Global Shrikant Akolkar - Nuvama Wealth Saion Mukherjee - Nomura Operator Ladies and gentlemen, good evening, and welcome to Quarter Four and Full Year FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. [Operator Instructions] I now hand the conference over to Ms.
Dr. Reddy's Q4 & Full Year FY25 Financial Results
businesswire.com
2025-05-09 14:53:00HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
zacks.com
2025-03-31 10:31:49Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
prnewswire.com
2025-03-27 11:47:00GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.